According to the National Eye Institute of the United States, the drug Lucentis company Roche AG works better than the exclusive use of lasers to treat a common type of blindness in people with diabetes.
At a conference sponsored by the institute, the Network of Diabetic Retinopathy Clinical Research, reported that: “Lucentis, known generically as ranibizumab, was much more effective than single treatment with laser in various types of retinal problems.”
Lucentis is a particle called the immune system engineered monoclonal antibody that targets the blood vessels of the eye. The drug is already approved to treat macular degeneration, a condition that causes blindness and is caused by the growth of vessels in the retina and the possibility of using the drug to millions of diabetics opens a huge market.
The national network of researchers evaluated 691 patients who underwent random laser treatment, the laser or laser Lucentis with another drug called triamcinolone.
The team found that adding injections of Lucentis to stop blood vessel growth at the molecular level showed better effects.
“After a year, almost 50 percent of eyes treated with ranibizumab and laser immediate or delayed showed a substantial improvement in vision,” he wrote in a report to be published in the journal Ophthalmology.
On the other hand, only 28 percent of patients treated only with laser or triamcinolone showed this improvement. Most of the positive effects were seen after two months of injections.
Possibility Related Posts:
Posted in Diabetes Therapy | 
Tags: blurred vision, diabetes, Diabetes Therapy, diabetes treatment, drugs, medicine, neuropathy, therapy, treatment